Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5277990
Max Phase: Preclinical
Molecular Formula: C38H39ClN8O7S
Molecular Weight: 787.30
Associated Items:
ID: ALA5277990
Max Phase: Preclinical
Molecular Formula: C38H39ClN8O7S
Molecular Weight: 787.30
Associated Items:
Canonical SMILES: Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)NCCCCNC(=O)COc1cccc3c1C(=O)N(C1CCC(=O)NC1=O)C3O)c1nnc(C)n1-2
Standard InChI: InChI=1S/C38H39ClN8O7S/c1-19-20(2)55-38-31(19)33(22-9-11-23(39)12-10-22)42-25(34-45-44-21(3)46(34)38)17-29(49)40-15-4-5-16-41-30(50)18-54-27-8-6-7-24-32(27)37(53)47(36(24)52)26-13-14-28(48)43-35(26)51/h6-12,25-26,36,52H,4-5,13-18H2,1-3H3,(H,40,49)(H,41,50)(H,43,48,51)/t25-,26?,36?/m0/s1
Standard InChI Key: UTOUETFTDAGMCH-UTOGBMEWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 787.30 | Molecular Weight (Monoisotopic): 786.2351 | AlogP: 3.53 | #Rotatable Bonds: 12 |
Polar Surface Area: 197.21 | Molecular Species: NEUTRAL | HBA: 12 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 15 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.55 | CX Basic pKa: 4.44 | CX LogP: 2.37 | CX LogD: 2.37 |
Aromatic Rings: 4 | Heavy Atoms: 55 | QED Weighted: 0.12 | Np Likeness Score: -0.76 |
1. Tang P, Zhang J, Liu J, Chiang CM, Ouyang L.. (2021) Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development., 64 (5.0): [PMID:33616410] [10.1021/acs.jmedchem.0c01487] |
Source(1):